ArticleHereditas2025
Shenling Baizhu San attenuates testicular spermatogenic dysfunction in hyperuricemic mice via dual modulation of MAPK/NF-κB and NLRP3 inflammasome pathways.
Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploring the role of febuxostat's drug target XOR in erectile dysfunction: insights from human genetics and rat models.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
contextHyperuricemia (HUA) is a known factor contributing to testicular spermatogenic dysfunction. Shenling Baizhu San (SLBZS), a traditional Chinese medicine compound, has demonstrated efficacy in reducing uric acid levels. However, its specific impact on testicular spermatogenic function in mice with HUA remains unclear.
objectiveTo investigate the impact and mechanism of SLBZS on testicular spermatogenic function in HUA mice. MATERIALS AND
methodsA hyperuricemia-induced spermatogenic dysfunction model was created by administering intraperitoneal injections of potassium oxonate (600 mg/kg/d) for seven days. Following model establishment, 48 Balb/c mice were randomly divided into six groups: control, model, low-dose SLBZS (5.04 g/kg/d), medium-dose SLBZS (10.07 g/kg/d), high-dose SLBZS (20.14 g/kg/d), and febuxostat (10 mg/kg/d). All groups, except the control, underwent model induction, followed by specific interventions. Subsequent analyses included serum uric acid levels, testicular and epididymal indices, histopathological assessments, sperm quality, oxidative stress and inflammation markers, and the expression of proteins related to apoptosis and inflammation signaling pathways.
resultsSLBZS markedly enhanced sperm quality, testicular and epididymal indices, and serum uric acid levels in mice, while ameliorating histopathological lesions in testicular tissue. Additionally, SLBZS significantly reduced oxidative stress, serum inflammation markers, and testicular cell apoptosis, with the high-dose group showing superior effects compared to the febuxostat group. Further investigation revealed that SLBZS inhibited the expression and phosphorylation of proteins in the MAPK/NF-κB pathway and suppressed the expression of proteins in the NLRP3 inflammasome pathway. DISCUSSION AND
conclusionsSLBZS potentially modulates the MAPK/NF-κB and NLRP3 inflammasome signaling pathways, thereby suppressing inflammatory responses and enhancing spermatogenesis in the testes of HUA mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.